JP Morgan Chase’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.4M | Buy |
915,185
+429,482
| +88% | +$13.9M | ﹤0.01% | 1709 |
|
|
2026
Q1 | $14.5M | Sell |
485,703
-61,125
| -11% | -$1.96M | ﹤0.01% | 2355 |
|
|
2025
Q4 | $19.2M | Sell |
546,828
-2,030,259
| -79% | -$71.9M | ﹤0.01% | 2097 |
|
|
2025
Q3 | $67.7M | Sell |
2,577,087
-61,968
| -2% | -$1.85M | ﹤0.01% | 1218 |
|
|
2025
Q2 | $69.9M | Sell |
2,639,055
-487,447
| -16% | -$12.8M | ﹤0.01% | 1133 |
|
|
2025
Q1 | $75.5M | Buy |
3,126,502
+968,959
| +45% | +$30.6M | 0.01% | 1080 |
|
|
2024
Q4 | $86.8M | Buy |
2,157,543
+41,105
| +2% | +$2.34M | 0.01% | 1006 |
|
|
2024
Q3 | $134M | Sell |
2,116,438
-135,233
| -6% | -$7.93M | 0.01% | 836 |
|
|
2024
Q2 | $119M | Buy |
2,251,671
+1,211,513
| +116% | +$79.4M | 0.01% | 836 |
|
|
2024
Q1 | $85.3M | Buy |
1,040,158
+472,566
| +83% | +$21M | 0.01% | 1009 |
|
|
2023
Q4 | $10.6M | Buy |
567,592
+10,424
| +2% | +$136K | ﹤0.01% | 2419 |
|
|
2023
Q3 | $6.17M | Buy |
557,168
+10,635
| +2% | +$152K | ﹤0.01% | 2676 |
|
|
2023
Q2 | $8.86M | Buy |
546,533
+543,895
| +20,618% | +$11.4M | ﹤0.01% | 2393 |
|
|
2023
Q1 | $43.7K | Buy |
2,638
+2,140
| +430% | +$22.1K | ﹤0.01% | 5751 |
|
|
2022
Q4 | $4K | Sell |
498
-28,510
| -98% | -$127K | ﹤0.01% | 6218 |
|
|
2022
Q3 | $80K | Sell |
29,008
-17,077
| -37% | -$55.9K | ﹤0.01% | 5387 |
|
|
2022
Q2 | $134K | Buy |
46,085
+13,192
| +40% | +$32.6K | ﹤0.01% | 5278 |
|
|
2022
Q1 | $99K | Buy |
32,893
+5,606
| +21% | +$20.1K | ﹤0.01% | 5518 |
|
|
2021
Q4 | $124K | Buy |
27,287
+1,152
| +4% | +$6.46K | ﹤0.01% | 5587 |
|
|
2021
Q3 | $164K | Sell |
26,135
-737
| -3% | -$4.55K | ﹤0.01% | 5332 |
|
|
2021
Q2 | $160K | Sell |
26,872
-12,551
| -32% | -$74.5K | ﹤0.01% | 5341 |
|
|
2021
Q1 | $251K | Buy |
39,423
+9,623
| +32% | +$67.7K | ﹤0.01% | 5059 |
|
|
2020
Q4 | $167K | Buy |
29,800
+5,358
| +22% | +$32.5K | ﹤0.01% | 4867 |
|
|
2020
Q3 | $145K | Buy |
24,442
+2,390
| +11% | +$16.5K | ﹤0.01% | 4528 |
|
|
2020
Q2 | $159K | Buy |
22,052
+597
| +3% | +$3.96K | ﹤0.01% | 4373 |
|
|
2020
Q1 | $101K | Buy |
21,455
+20
| +0.1% | +$123 | ﹤0.01% | 4509 |
|
|
2019
Q4 | $172K | Hold |
21,435
| – | – | ﹤0.01% | 4731 |
|
|
2019
Q3 | $147K | Buy |
21,435
+3,611
| +20% | +$26.8K | ﹤0.01% | 4760 |
|
|
2019
Q2 | $149K | Buy |
17,824
+2,983
| +20% | +$25.5K | ﹤0.01% | 4779 |
|
|
2019
Q1 | $148K | Sell |
14,841
-479
| -3% | -$4.01K | ﹤0.01% | 4740 |
|
|
2018
Q4 | $117K | Buy |
15,320
+3,309
| +28% | +$39.6K | ﹤0.01% | 4788 |
|
|
2018
Q3 | $209K | Buy |
12,011
+3,168
| +36% | +$37.7K | ﹤0.01% | 4677 |
|
|
2018
Q2 | $84K | Buy |
+8,843
| New | +$58.8K | ﹤0.01% | 4897 |
|
Other funds holding VKTX
JP Morgan Chase's VKTX Position: Q2 2026 in Review
JP Morgan Chase increased its Viking Therapeutics (VKTX) stake by 88% in Q2 2026, buying an estimated $13.9M and bringing the position to 915,185 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.
JP Morgan Chase first reported a position in VKTX in Q2 2018 and has held it in 33 quarters since. The position peaked at $134M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- JP Morgan Chase held 915,185 shares of Viking Therapeutics worth $36.4M as of Q2 2026.
- JP Morgan Chase bought 429,482 Viking Therapeutics shares in Q2 2026, an estimated $13.9M.
- Viking Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1709 holding.
- JP Morgan Chase first reported a position in Viking Therapeutics in Q2 2018 and has held it in 33 quarters since.
- JP Morgan Chase's Viking Therapeutics position peaked at $134M in Q3 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.